Guggenheim Capital LLC Buys 82,394 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Guggenheim Capital LLC boosted its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 341.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 106,538 shares of the company's stock after buying an additional 82,394 shares during the quarter. Guggenheim Capital LLC's holdings in Dr. Reddy's Laboratories were worth $1,682,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. AIA Group Ltd increased its position in shares of Dr. Reddy's Laboratories by 441.7% in the fourth quarter. AIA Group Ltd now owns 145,150 shares of the company's stock valued at $2,292,000 after acquiring an additional 118,357 shares during the last quarter. Vanguard Group Inc. raised its position in Dr. Reddy's Laboratories by 397.2% during the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after acquiring an additional 3,911,404 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its position in Dr. Reddy's Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after acquiring an additional 9,373,412 shares in the last quarter. Van ECK Associates Corp lifted its stake in Dr. Reddy's Laboratories by 609.4% in the fourth quarter. Van ECK Associates Corp now owns 5,838 shares of the company's stock valued at $92,000 after acquiring an additional 5,015 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Dr. Reddy's Laboratories by 400.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock valued at $8,373,000 after acquiring an additional 427,573 shares during the period. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Performance

Shares of Dr. Reddy's Laboratories stock traded down $0.20 during trading on Friday, hitting $13.81. 486,217 shares of the stock were exchanged, compared to its average volume of 1,465,892. Dr. Reddy's Laboratories Limited has a 1-year low of $12.26 and a 1-year high of $16.89. The stock has a market capitalization of $11.52 billion, a price-to-earnings ratio of 21.98 and a beta of 0.51. The company has a fifty day moving average price of $13.16 and a 200-day moving average price of $14.24. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.